HLA-B*5701 and Abacavir Hypersensitivity: A Pharmacogenomic…

What the HLA-B*5701 Abacavir Hypersensitivity Screen Is

The HLA-B*5701 allele is a specific variant of human leukocyte antigen B that plays a critical role in drug metabolism and immune response. Individuals who carry this allele are at risk for developing severe hypersensitivity reactions, particularly when prescribed abacavir, an antiretroviral medication used to treat HIV.

The HLA-B*5701 screening test is designed to identify individuals with this genetic marker before they receive abacavir, allowing healthcare providers to avoid prescribing the drug in those at high risk and thus prevent serious adverse reactions.

Why It Matters

The importance of HLA-B*5701 screening cannot be overstated. By identifying patients who are carriers of this allele, healthcare providers can make informed decisions about drug therapy, reducing the risk of life-threatening hypersensitivity reactions such as Stevens-Johnson syndrome and toxic epidermal necrolysis.

This genetic test is an example of pharmacogenomics in action, demonstrating how understanding individual genetic differences can lead to safer and more effective medical treatments.

live demo · related simulation● LIVE

How the Test Works

The HLA-B*5701 screening test typically involves a blood sample from the patient. The DNA is extracted, and specific regions of the genome are analyzed to determine if the individual has inherited one or two copies of the HLA-B*5701 allele.

If the test result is positive for HLA-B*5701, the healthcare provider will avoid prescribing abacavir and may opt for alternative antiretroviral drugs that do not pose a similar risk.

Real-World Applications

The application of HLA-B*5701 screening in clinical practice has significantly reduced the incidence of severe abacavir-induced hypersensitivity reactions. This test is now widely used in many countries as part of routine HIV treatment protocols.

Beyond its immediate impact on patient safety, this example highlights the broader potential of pharmacogenomics to personalize medicine and improve public health outcomes.

Frequently asked questions

How common is the HLA-B*5701 allele in different populations?

The frequency of the HLA-B*5701 allele varies among different ethnic groups, with higher prevalence rates observed in certain Asian and Mediterranean populations.

What happens if a patient is prescribed abacavir despite being positive for HLA-B*5701?

If a patient who tests positive for HLA-B*5701 is prescribed abacavir, they are at high risk of developing severe hypersensitivity reactions. Immediate discontinuation of the drug and alternative treatment options must be considered.

Can other drugs besides abacavir cause similar hypersensitivity reactions related to HLA-B*5701?

While abacavir is the most well-known drug associated with HLA-B*5701-related hypersensitivity, other drugs such as allopurinol and carbamazepine can also trigger severe reactions in individuals carrying this allele.

Is there a risk of false positives or negatives from the HLA-B*5701 test?

Like all genetic tests, there is a possibility of false positive or negative results. However, modern testing methods are highly accurate and reliable, with sensitivity and specificity rates that minimize these risks.

Try it live

Everything above runs in your browser — open HLA-B*5701 Abacavir Hypersensitivity Screen and change the parameters while it is running. Nothing is installed, nothing is uploaded, the whole model lives in one tab.

▶ Open HLA-B*5701 Abacavir Hypersensitivity Screen simulation

HLA-B*5701 and Abacavir Hypersensitivity: A Pharmacogenomic Insight